Lucky Minerals Inc. is subject to a failure-to-file cease trade order issued by the Securities Commission in March, 2025 for failure to file its annual financial statements, annual management's ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an ...
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback